Skip to main content
. 2021 Mar 24;9(3):e001458. doi: 10.1136/jitc-2020-001458

Figure 1.

Figure 1

Efficacy of anti-programmed cell death 1 (anti-PD-1) immune checkpoint inhibitor (ICI) therapy in patients with sarcoma. (A) Waterfall plot of % change of tumor burden from anti-PD-1 ICI therapy start until best response from center 1 patients. The dashed lines indicate the margins for PD (+20% change of tumor burden) and PR (−30% change of tumor burden). (B) Objective response rate (ORR) and clinical benefit rate (CBR) as % of patients (both centers). (C) Progression-free survival (PFS) and (D) overall survival (OS) of patients with sarcoma from anti-PD-1 ICI therapy start in months (both centers). Vertical lines indicate censored patients at last follow-up. CB, clinical benefit; OR, objective response; PD, progressive disease; PD-1, programmed cell death 1.